Advanced Flower Capital: A Battered BDC Finds a New Lending Vintage

Lower-middle-market pivot and legacy cannabis resolutions drive a 27.7% quarterly surge

AFCG · Earnings Call · 2026-08-13

Advanced Flower Capital (AFCG) is a small-cap BDC that has seen its stock jump 27.7% in the last 90 days, yet it remains 79% below its 2021 peak. The Q2 2026 earnings call reveals why: the company is aggressively pivoting away from its cannabis-lending roots toward lower-middle-market private credit, while simultaneously resolving its legacy troubled loans. This is a genuine strategic inflection point, backed by tangible progress on both fronts.

A Compelling Vintage in Private Credit

The biggest change is the explicit embrace of the lower-middle-market lending opportunity. As President Robyn Tannenbaum put it on the call,

The private credit ecosystem is experiencing stress... As a result, we continue to believe the lower middle market offers 1 of the most compelling risk adjusted return investment opportunities in private credit today.
Robyn Tannenbaum, President and Chief Investment Officer · 2026-08-13

This framing is new—the company has historically been a cannabis-focused lender. The middle market now dominates the pipeline, with CEO Daniel Neville acknowledging lumpiness while pointing to a $1.3 billion opportunity set: “originations are going to be lumpy. You saw it in Q1, we did about $80 million. We did less in Q2.” — Daniel Neville, Chief Executive Officer · 2026-08-13 The rising tide of defaults across private credit is paradoxically creating opportunity, as weaker lenders retreat, leaving room for disciplined capital deployment. The pivot was already anticipated earlier in the year; Daniel noted in May that while yields would compress, borrower quality would improve: “we would expect the yields to move down a touch into the low double-digit range on an overall basis, but we expect the quality of the borrowers and the counterparties on the sponsor side to improve significantly in the lower middle market.” — Daniel Neville, Chief Executive Officer · 2026-05-07

Legacy Cannabis Woes: A Path to Resolution?

The legacy loan book continues to weigh on the company, but this quarter brought tangible progress. For the Devi loan, the receiver is executing on asset sales, and a binding term sheet was signed. As Daniel noted, “Subsequent to quarter end, Devi earned a $2 million nonrefundable deposit on the purchase, we expect the transaction to close this year.” — Daniel Neville, Chief Executive Officer · 2026-08-13 Meanwhile, DMA closed sales of two of its three dispensaries, and the Justice Grown situation is moving toward foreclosure. The company is also using its expanded BDC mandate to enter new verticals, such as the recently funded behavioral health platform loan. However, the industry-wide struggle for equity capital remains a key concern, keeping the company cautious on new cannabis exposure.

Capital Allocation: Buying Back Stock at a Steep Discount

Perhaps the most striking move was the aggressive share repurchase program. Management bought back 839,000 shares at an average price of $3.29, which was accretive to NAV by $0.17 per share. With the stock trading at just 0.4x book value, this is a rational deployment of capital that signals management confidence. The company ended the quarter with $106.5 million in cash and a NAV of $8.25 per share, providing ample dry powder for both buybacks and new investments. The broader private credit stress has also reshaped the competitive landscape, as Robyn explained: “Banks... hold indirect exposure through leveraged facilities... and that exposure is now drawing increased scrutiny.” — Robyn Tannenbaum, President and Chief Investment Officer · 2026-08-13 This is creating a tailwind for focused lenders like AFCG.

What It Means

This is a genuine turnaround story in the making. The 90-day stock price surge reflects growing recognition that the company is systematically converting legacy problem loans into cash while building a new, higher-quality lending book. The fundamentals support the narrative—Price/Book has compressed from 1.1x in 2024 to 0.4x today, but NAV per share rose $0.35 this quarter. The market is slowly pricing in the evolution, and the combination of legacy resolution, disciplined capital deployment, and a favorable private credit environment makes this a name worth watching.